Countries do not export pills. They export trust

Just a few years ago, discussions about Kazakhstan’s pharmaceutical exports sounded more like conversations about future ambitions than about a real economic trend. Today, that picture is changing. In 2025, domestic manufacturers produced pharmaceutical products worth $366.5 million, and around 18-19% of that output was exported. Medicines made in Kazakhstan are now shipped to about 12 countries. These numbers may not seem dramatic at first glance, but they signal something important. The industry is moving beyond the stage of serving only the domestic market and entering a new phase of growth, expansion, and international presence. The key question is no longer whether Kazakhstan can export medicines. That question has already been answered. The more important question is how these early export shipments can evolve into a sustainable system that allows domestic producers to secure meaningful positions in regional markets by 2030.

This is where many people make the same mistake. Pharmaceutical exports are often viewed as a simple trade activity: produce a medicine, send it across the border, and sell it abroad. In reality, pharmaceuticals work very differently from most industries. In many markets, buyers focus mainly on price and quality. In pharmaceuticals, trust matters just as much, if not more. In many ways, the global pharmaceutical market is a market of trust. Alongside medicines, countries export their reputation, the credibility of their regulatory systems, the quality of their inspections, and their ability to maintain reliable supply over many years. That is why countries compete not only through factories and production costs. Increasingly, they compete through the strength of their entire pharmaceutical ecosystem.

The global landscape for medicine supply has changed significantly over the past few years. The pandemic exposed the vulnerabilities of long supply chains. Geopolitical tensions and logistics disruptions that followed forced many governments to rethink how they approach medicine security. In the past, the main goal was to find the lowest-cost supplier. Today, reliability, resilience, and predictability have become far more important. Countries are looking for regional partners that can guarantee stable deliveries even during periods of uncertainty. This shift creates an opportunity that Kazakhstan did not have a decade ago.

The country sits at the crossroads of Central Asia, the Caucasus, Russia, China, and the Middle East. However, geography alone never creates an advantage. Many countries have occupied strategic trade routes without turning that position into long-term economic success. Location becomes valuable only when it is supported by industrial capacity and the ability to integrate into international value chains. Kazakhstan’s pharmaceutical sector has been building that foundation. Companies have modernized production facilities, adopted international quality standards, and started entering foreign markets. Yet the next stage will be much harder than the previous one. Building a factory is difficult. Building an export system is even harder.

One of the biggest mistakes the industry could make would be trying to compete on price alone. The market for simple generic medicines is already crowded. India and China have manufacturing scale that is extremely difficult to match. More importantly, an export strategy based only on lower prices rarely works in the long run. There will always be another producer willing to offer an even cheaper product. The most successful pharmaceutical exporters have usually followed a different path. Rather than producing everything, they focus on specific strengths and market niches. For Kazakhstan, that could mean expanding into more complex dosage forms, biosimilars, hospital medicines, treatments for socially significant diseases, and medical devices. In these segments, success depends not only on cost but also on quality, consistency, and technological capability.

At the same time, having a good product does not automatically guarantee export success. One of the biggest barriers remains the cost of entering a new market. Registering a medicine abroad requires time, money, and expertise. Documentation must be adapted. Companies need to work with local regulators. Pharmacovigilance systems must be established. Distribution networks have to be built. In some cases, additional audits and studies are required. For large multinational corporations, these costs are part of doing business. For many manufacturers from emerging markets, they can become a major obstacle to growth. That is why pharmaceutical exports rarely succeed through company efforts alone. In nearly every country that has built a strong pharmaceutical export sector, governments have acted as infrastructure partners.

This issue is becoming especially important for Kazakhstan now that the industry has gained its first export experience. Shipments to twelve countries show that products made by domestic manufacturers are already finding demand beyond the local market. Yet there is a major difference between having several export contracts and having a fully developed export industry. Moving to the next level will require an ecosystem that helps companies through the entire process, from market entry to integration into healthcare systems abroad. This is about much more than promoting products internationally. Recognition of quality standards, support for registration procedures, export financing, risk insurance, and long-term partnerships all play a critical role.

In reality, Kazakhstan is approaching a stage where pharmaceutical exports are no longer just an industry issue. They are becoming part of a broader economic strategy. The difference between a resource-based economy and a technology-driven economy is not only the type of products they sell. It is also about where value comes from. Resource industries rely primarily on natural assets. Pharmaceuticals depend on knowledge, technology, skilled people, quality systems, and trust. That is why the growth of pharmaceutical exports can also serve as a measure of industrial maturity and a country’s ability to compete in more sophisticated parts of the global economy.

Today, Kazakhstan has already moved beyond the stage where pharmaceutical exports are viewed as a distant goal. A manufacturing base exists. Initial export markets have been established. Companies have gained international experience. The next stage will not be defined by the number of boxes shipped abroad but by the ability to transform exports into a sustainable growth system. If that happens, today’s twelve export destinations could become the starting point for a much broader international footprint. By 2030, Kazakhstan could position itself not simply as a producer of medicines, but as one of the region’s centers of pharmaceutical trust. Because in modern pharmaceuticals, countries do not really export pills. They export quality, reputation, supply reliability, and the ability to become a trusted part of another country’s healthcare system. Those are the assets that secure a lasting place in the global pharmaceutical market and create long-term competitive advantages.